Clevidipine butyrate is an ultrashort-acting intravenous calcium channel blocker that allows for precise blood pressure control in critical care settings.
Answers are grounded in this paper and cite their sources.
May enable precise BP titration in acute settings; leaves open comparative outcome trials versus other agents.
Role of clevidipine butyrate in the treatment of acute hypertension in the critical care setting: a review Ahmed S Awad, Michael E GoldbergDepartment of Anesthesiology, Cooper University Hospital, UMDNJ-Robert Wood Johnson Medical School, Camden Campus, Camden, New Jersey, USAAbstract: Acutely elevated blood pressure in the critical care setting is associated with a higher risk of acute end-organ damage (eg, myocardial ischemia, stroke, and renal failure) and perioperative bleeding. Urgent treatment and careful blood pressure control are crucial to prevent significant morbidity. Clevidipine butyrate (Cleviprex™) is an ultrashort-acting, third-generation intravenous calcium channel blocker. It is an arterial-selective vasodilator with no venodilatory or myocardial depressive effects. Clevidipine has an extremely short half-life of approximately 1 minute as it is rapidly metabolized by blood and tissue esterases. These metabolites are then primarily eliminated through urine and fecal pathways. The rapid onset and the short duration of action permit tighter and closer adjustment of the blood pressure than is possible with other intravenous agents.
No takes yet. Share an insight, caveat, or question.
Goldberg et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: